NAS
CRL icon

Nykredit A/S’s Charles River Laboratories CRL Stock Holding History

Nykredit A/S’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339K Buy
+1,495
New +$266K ﹤0.01% 818

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nykredit A/S's CRL Position: Q2 2026 in Review

Nykredit A/S opened a new position in Charles River Laboratories (CRL) in Q2 2026: 1,495 shares worth $339K. The stake represents ﹤0.01% of the portfolio and ranks #818 among its holdings.

436 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Nykredit A/S held 1,495 shares of Charles River Laboratories worth $339K as of Q2 2026.
  • Charles River Laboratories was a new Nykredit A/S position in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #818 holding.
  • 436 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.